文献速递慢性肾脏病肾小球疾病

从进展到缓解:慢性肾脏病治疗成功的新范式

From progression to remission: a new paradigm for success in chronic kidney disease.
PubMed 文献 · Kidney Int · 2025-11-06

近期SGLT2抑制剂、非甾体盐皮质激素受体拮抗剂、GLP-1受体激动剂及IgA肾病靶向免疫治疗的关键试验表明,持续保持eGFR和尿白蛋白正常化已成为糖尿病及肾小球疾病患者的现实目标。缓解定义为eGFR斜率<1 ml/min/1.73 m2/年或尿白蛋白正常且eGFR正常,早期发现和联合治疗使其更易实现。作者主张肾脏病治疗重点应从延缓进展转向维持肾脏健康。

要点

  • 缓解定义为eGFR斜率<1 ml/min/1.73 m2/年或尿白蛋白正常且eGFR正常。
  • SGLT2抑制剂等四类疗法使糖尿病和肾小球疾病缓解成为现实目标。
  • 早期发现和联合治疗是实现缓解的关键,需推行人群筛查和指南导向治疗。

核心结论

  • 慢性肾脏病治疗成功标准应从延缓进展转变为实现缓解。
  • 缓解在糖尿病和肾小球疾病中已日益可及,应成为标准治疗。

研究设计与样本

  • 本文为综述,总结SGLT2抑制剂、非甾体盐皮质激素受体拮抗剂、GLP-1受体激动剂及IgA肾病靶向免疫治疗的关键试验。

主要发现

  • 关键试验显示持续保持eGFR和尿白蛋白正常化已成为现实目标。
  • 缓解定义为eGFR斜率<1 ml/min/1.73 m2/年或尿白蛋白正常且eGFR正常。
  • 早期检测和联合治疗使缓解更易实现。

关键数值与推荐

  • 缓解标准:eGFR斜率<1 ml/min/1.73 m2/年,或尿白蛋白正常且eGFR正常。

临床怎么用

  • 肾脏病治疗重点应转向维持肾脏健康而非仅延缓进展。
  • 推行人群筛查、风险分层和指南导向治疗以扩大缓解机会。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Recent advances in treatment of chronic kidney disease have changed the clinical paradigm from slowing inevitable progression to achievable remission. Landmark trials involving sodium-glucose cotransporter 2 inhibitors, nonsteroidal mineralocorticoid receptor antagonists, glucagon-like peptide 1 receptor agonists, and targeted immunotherapies for IgA nephropathy demonstrate that sustained estimated glomerular filtration rate preservation and normalization of albuminuria are now realistic goals in both diabetic and glomerular kidney diseases. Remission, defined by estimated glomerular filtration rate slopes of <1 ml/min per 1.73 m2 per year or the absence of albuminuria with a normal estimated glomerular filtration rate, is increasingly attainable, especially with early detection and combination therapy. We believe that these findings mandate a shift in nephrology's therapeutic focus-from delaying progression to maintaining kidney health. Population-based screening, risk stratification, and implementation of guideline-directed therapy are essential to scale this opportunity. The time has come to redefine success in chronic kidney disease: remission is not only possible-it must become our standard of care.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Tangri N, Neuen BL, Cherney DZ, et al. From progression to remission: a new paradigm for success in chronic kidney disease. Kidney Int. 2025. PMID: 41205673. doi:10.1016/j.kint.2025.10.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。